Date: 2012-07-07
Type of information: R&D agreement
Compound:
Company: Novo Nordisk (Denmark) Benaroya Research Institute (USA)
Therapeutic area: Autoimmune diseases – Digestive diseases - Inflammatory diseases - Rheumatic diseases
Type agreement: R&D
Action mechanism:
Disease: rheumatoid arthritis, inflammatory bowel disease, lupus
Details: Novo Nordisk and Benaroya Research Institute at Virginia Mason (BRI), a non-profit biomedical research institute in Seattle, have announced a three-year collaborative agreement to potentially speed-up translational research of the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease and lupus. The agreement establishes how Novo Nordisk and BRI research scientists and BRI clinicians will collaboratively develop studies to better understand changes in the immune systems of patients living with these autoimmune diseases. The intent is to develop better therapies and improve how these treatments are used.
Benaroya Research Institute at Virginia Mason maintains one of the world’s most robust biobanks for the study of autoimmune disorders, with samples and patient histories dating back to 2000. BRI actively maintains biorepositories for eleven different autoimmune disorders and immune mediated diseases including multiple sclerosis, Type 1 diabetes, lupus, rheumatoid arthritis, scleroderma, inflammatory bowel disease, allergy, asthma, lung disease and transplant recipients. BRI also maintains a registry of healthy people for comparison purposes.
Financial terms:
Latest news:
